menu
    • menu
    [{"orgOrder":0,"company":"Emergence Therapeutics","sponsor":"Mablink Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Emergence Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Emergence Therapeutics \/ Mablink Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Emergence Therapeutics \/ Mablink Bioscience"},{"orgOrder":0,"company":"Emergence Therapeutics","sponsor":"Pontifax Venture Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Series A Financing","leadProduct":"ETx-22","moa":"Nectin-4","graph1":"Oncology","graph2":"Preclinical","graph3":"Emergence Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Emergence Therapeutics \/ Pontifax Venture Capital","highestDevelopmentStatusID":"4","companyTruncated":"Emergence Therapeutics \/ Pontifax Venture Capital"},{"orgOrder":0,"company":"Emergence Therapeutics","sponsor":"Synaffix","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Emergence Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Emergence Therapeutics \/ Emergence","highestDevelopmentStatusID":"4","companyTruncated":"Emergence Therapeutics \/ Emergence"},{"orgOrder":0,"company":"Emergence Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"Enfortumab Vedotin","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Emergence Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Emergence Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Emergence Therapeutics \/ Eli Lilly"}]

    Find Clinical Drug Pipeline Developments & Deals by Emergence Therapeutics

    Menu

    Emergence Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Emergence Therapeutics

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Emergence Therapeutics

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enfortumab Vedotin

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Heidelberg Pharma Sells Minority Shareholding in Emergence Therapeutics

                            Details : Through the acquisition, Eli gains access to Emergence's ADC pipeline, including ETx-22 (enfortumab vedotin), which targets Nectin-4 and is being developed for bladder, triple-negative breast cancer and malignancies with moderate and low Nectin-4 express...

                            Brand Name : ETx-22

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 29, 2023

                            Lead Product(s) : Enfortumab Vedotin

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Emergence Therapeutics

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Emergence Therapeutics

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody-drug Conjugate

                            Therapeutic Area : Technology

                            Study Phase : Preclinical

                            Recipient : Synaffix

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Emergence Therapeutics Licenses Synaffix ADC Technology Platform in $360M Deal

                            Details : Emergence will be responsible for the research, development, manufacturing and commercialization of the ADCs. Synaffix will be responsible for the manufacturing of components that are specifically related to its proprietary technologies.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : $360.0 million

                            September 06, 2022

                            Lead Product(s) : Antibody-drug Conjugate

                            Therapeutic Area : Technology

                            Highest Development Status : Preclinical

                            Recipient : Synaffix

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Emergence Therapeutics

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Emergence Therapeutics

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ETx-22

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Pontifax Venture Capital

                            Deal Size : $98.3 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Emergence Therapeutics Raises €87 million Series A Financing to Advance Nectin-4 ADC

                            Details : Proceeds from this funding round will be used to advance the company’s next-generation antibody drug conjugate (ADC) including ETx-22, targeting Nectin-4 to clinical proof-of-concept as well as the development of additional ADC programs.

                            Brand Name : ETx-22

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 07, 2021

                            Lead Product(s) : ETx-22

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Pontifax Venture Capital

                            Deal Size : $98.3 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Emergence Therapeutics

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Emergence Therapeutics

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody-drug Conjugate

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Mablink Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Mablink Bioscience and Emergence Therapeutics Enter Into a Licensing Agreement to Develop Antibody Drug Conjug...

                            Details : Under the terms of the agreement, Emergence Therapeutics will use a PSARlink™ drug-linker developed by Mablink to develop an ADC targeting Nectin-4, a protein overexpressed in several severe cancers.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 21, 2021

                            Lead Product(s) : Antibody-drug Conjugate

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Mablink Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth